The annual ASCO Breakthrough conference stands as a premier Asia-Pacific oncology event, uniting international experts to exchange groundbreaking research, clinical milestones, and innovative treatment strategies that are reshaping the future of cancer care.
This year’s hybrid event is taking place in Singapore and online from June 25–27, 2026. Over three days, the global oncology community is engaging in high-impact scientific sessions, case-based discussions, and cutting-edge abstract presentations designed to spark collaboration and accelerate worldwide progress in oncology.
Dr. Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shares his top takeaways and key highlights directly from ASCO Breakthrough 2026:
An Inspiring Start to Day 2 of ASCO Breakthrough
“Inspiring opening to Day 2 of ASCO Breakthrough with Dr David Goldstein setting up the discussion about how AI can help to streamline cancer diagnostics and logistics.”
AI Governance and Health Equity
“Poignant discussion about governance in AI and how AI can be used to circumvent inequities in care especially in developing countries by Naveen Nagar at 2026 ASCO Breakthrough Meeting.”
AI Bridging Radiology and Pathology
“Can AI bridge the gap between radiology and pathology to transform cancer diagnostics?
At the 2026 ASCO Breakthrough Meeting, Daniel Truhn explored how artificial intelligence can integrate imaging and pathology to identify clinically meaningful biomarkers, creating a more accurate and efficient pathway to preliminary cancer diagnosis. Rather than replacing clinicians, AI has the potential to connect complementary data sources, uncover patterns invisible to the human eye, and advance precision oncology through multimodal diagnostics. The future of cancer diagnosis may not rely on a single modality-but on intelligently combining them.”
AI Transforming Multidisciplinary Cancer Care
“How can AI make multidisciplinary cancer care smarter-not just faster?
Outstanding presentation by Dr. Arsela Prelaj at the 2026 ASCO Breakthrough Meeting on the rapidly evolving role of AI in oncology.
Key takeaways:
- AI-powered tumor boards can automate data aggregation and organization, reducing administrative burden and allowing clinicians to spend more time discussing complex cases and optimizing patient care.
- AI can accelerate the journey from bench to bedside by helping generate hypotheses, design experiments, and identify promising therapeutic strategies for clinical translation.
- Multimodal AI has the potential to integrate pathology, imaging, genomics, and clinical data to better match patients with the most appropriate immunotherapy and precision oncology treatments.
- Agentic AI represents the next frontier-autonomous systems capable of evaluating complex datasets and coordinating specialized AI agents. The challenge now lies in building the right architecture, governance, and clinical validation to implement these systems safely.
AI is evolving from a decision-support tool into an intelligent collaborator across the entire oncology ecosystem-from discovery to tumor boards to personalized cancer care.”
AI Expanding Access to Clinical Trials
“One of the greatest inequities in oncology is that many patients who could benefit from clinical trials are never identified.
Great presentation by Dr. Huren Sivaraj at the 2026 ASCO Breakthrough Meeting on how AI can help bridge this gap.
Key insights:
- AI embedded within the electronic medical record can automatically identify patients who may be eligible for clinical trials, reducing missed opportunities and easing the burden on busy clinicians.
- AI can rapidly analyze large, complex clinical datasets to match patients with appropriate studies more efficiently than traditional manual screening.
- Expanding these technologies could be especially impactful in low- and middle-income countries, where limited research infrastructure often restricts access to cutting-edge therapies.
AI has the potential to democratize clinical trial access-not by replacing clinicians, but by ensuring that more patients are considered for potentially life-changing research opportunities, regardless of where they receive care.”
AI Takes Center Stage in Oncology
“The excitement surrounding AI in oncology was on full display at the 2026 ASCO Breakthrough Meeting. An outstanding session, expertly moderated by Dr. Melvin L.K. Chua, brought together diverse perspectives on how artificial intelligence is reshaping cancer care-from clinical decision support and tumor boards to multimodal diagnostics and clinical trial matching.
The discussion was so engaging that the session ran over time-a testament to both the tremendous interest in the field and the thoughtful exchange of ideas.
Day 2 is already off to an incredible start, and it’s clear that AI will remain at the center of many of oncology’s most important conversations.”
MRD in Breast Cancer
“Great presentation from Dr Hiroji Iwata discussing MRD in breast cancer at the 2026 ASCO Breakthrough Meeting.”
MRD in Lung Cancer: The Next Frontier
“Standing room only for an outstanding presentation by Dr. Tony Mok at the 2026 ASCO Breakthrough Meeting on the evolving role of minimal residual disease (MRD) in lung cancer.
A fascinating discussion highlighted both the promise and the challenges of bringing MRD into routine clinical practice. Beyond the science, there was an important emphasis on equitable access to MRD testing, ensuring these advances benefit patients across diverse healthcare settings.
One of the most thought-provoking questions remains: MRD is clearly a powerful prognostic biomarker-but is it ready to become a predictive one? Should MRD positivity be used to escalate therapy, and could MRD clearance justify treatment de-escalation? While the potential is enormous, prospective clinical validation will be critical before MRD can routinely guide treatment decisions.
An exciting glimpse into the future of precision oncology and one of the highlights of the meeting.”
MRD-Guided Precision Oncology
“Another outstanding session at the 2026 ASCO Breakthrough Meeting by Dr. Jeanne Tie, highlighting the rapidly evolving role of circulating tumor DNA (ctDNA) and minimal residual disease (MRD) in guiding cancer therapy.
A key focus was the growing body of clinical trials evaluating whether MRD can safely guide treatment de-escalation. By using ctDNA as a highly sensitive marker of residual disease, investigators are exploring whether some patients can avoid unnecessary therapy while maintaining excellent outcomes.
This represents a fundamental shift toward response-adapted precision oncology-moving beyond traditional clinicopathologic risk factors and using real-time molecular biomarkers to individualize treatment intensity.
As evidence continues to mature, MRD-guided treatment strategies may redefine how we balance efficacy with toxicity, ensuring patients receive the right treatment for the right duration.”
Collaboration for Global Cancer Equity
“One of the most inspiring sessions of the day came from Dr. Neal Palafox, who delivered a remarkable ‘Tour de France’ through the Pacific Islands, highlighting both the challenges and the opportunities in advancing equitable cancer care across the region at ASCO Breakthrough 2026.
Rather than focusing solely on barriers, Dr. Palafox emphasized the power of regional collaboration-bringing countries, healthcare systems, and regional councils together to share expertise, strengthen infrastructure, and develop sustainable solutions to address longstanding disparities in cancer care.
The message was clear: no single nation can solve these challenges alone. Through partnerships, knowledge sharing, and coordinated action, meaningful progress toward equitable oncology care is possible.
A powerful reminder that innovation isn’t only about new therapies or technologies-it’s also about building the collaborations that ensure every patient, regardless of geography, has access to high-quality cancer care.”
Rethinking Cancer Care Access
“A powerful presentation by Dr. Bishal Gyawali at ASCO Breakthrough 2026 on rethinking how we address barriers to cancer care.
One of the most important messages: higher cancer care spending does not automatically translate into lower cancer mortality.
Improving outcomes requires more than simply spending more-it requires spending smarter, strengthening access, reducing low-value care, improving early detection, and ensuring that innovations reach the patients who need them most.
A timely reminder that progress in oncology must be measured not only by what we can develop, but by what we can deliver equitably.”
Read more about ASCO Breakthrough 2026 on OncoDaily.
